Licensing status

Publication and contact information


Pancreatic cancer

Toll-like receptor 7 (TLR7)

Patient sample and mouse studies suggest inhibiting TLR7 could help treat pancreatic cancer. In patient samples, TLR7 expression was greater in invasive pancreatic cancer than in preinvasive pancreatic intraepithelial neoplasias. In a mouse model of pancreatic cancer, oligonucleotide-mediated inhibition of TLR7 prevented malignant progression and stromal expansion. Next steps could include evaluating TLR7 inhibitors in animal models of pancreatic cancer.
At least four companies have compounds that inhibit TLR7 in Phase I testing or earlier to treat autoimmune- and inflammation-related conditions.

SciBX 5(41); doi:10.1038/scibx.2012.1081
Published online Oct. 18, 2012

Patent and licensing status unavailable

Ochi, A. et al. J. Clin. Invest.; published online Oct. 1, 2012;
Contact: George Miller, New York University School of Medicine, New York, N.Y.